Financiere des Professionnels Fonds d investissement inc. purchased a new stake in ADMA Biologics Inc (NASDAQ:ADMA – Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 70,832 shares of the biotechnology company’s stock, valued at approximately $638,000.
Several other large investors have also recently added to or reduced their stakes in ADMA. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its holdings in shares of ADMA Biologics by 36.2% during the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 20,064 shares of the biotechnology company’s stock worth $181,000 after buying an additional 5,338 shares in the last quarter. Fifth Third Bancorp boosted its holdings in shares of ADMA Biologics by 7,773.5% in the 1st quarter. Fifth Third Bancorp now owns 55,508 shares of the biotechnology company’s stock worth $500,000 after acquiring an additional 54,803 shares in the last quarter. PFG Investments LLC grew its position in ADMA Biologics by 4.1% during the 1st quarter. PFG Investments LLC now owns 222,729 shares of the biotechnology company’s stock worth $2,007,000 after acquiring an additional 8,728 shares during the last quarter. Y Intercept Hong Kong Ltd grew its position in ADMA Biologics by 1,508.1% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 1,075,422 shares of the biotechnology company’s stock worth $9,690,000 after acquiring an additional 1,008,548 shares during the last quarter. Finally, Peregrine Capital Management LLC increased its holdings in ADMA Biologics by 29.8% during the 1st quarter. Peregrine Capital Management LLC now owns 611,826 shares of the biotechnology company’s stock valued at $5,513,000 after purchasing an additional 140,370 shares in the last quarter. 75.68% of the stock is owned by institutional investors.
Insider Transactions at ADMA Biologics
In other news, Director Jerrold B. Grossman acquired 12,500 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the transaction, the director directly owned 513,884 shares in the company, valued at $4,116,210.84. This trade represents a 2.49% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.90% of the stock is currently owned by corporate insiders.
Key Stories Impacting ADMA Biologics
- Neutral Sentiment: Multiple plaintiff law firms announced or reiterated the August 10, 2026 deadline for investors to seek lead plaintiff status in the ADMA securities class action, keeping the litigation in focus for shareholders. Article Title
- Neutral Sentiment: Additional notices from firms including Faruqi & Faruqi, Kahn Swick & Foti, Robbins LLP, and Rosen Law Firm reinforce that a class action is already underway, suggesting ongoing legal overhang rather than any operational update. Article Title
- Neutral Sentiment: A Yahoo Finance-linked piece and other commentary reference class actions and probes over revenue allegations, indicating the market is still processing the underlying claims against ADMA Biologics. Article Title
ADMA Biologics Stock Down 1.1%
NASDAQ:ADMA opened at $8.71 on Friday. The stock’s fifty day moving average price is $8.46 and its two-hundred day moving average price is $12.28. ADMA Biologics Inc has a 52-week low of $7.21 and a 52-week high of $20.46. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. The company has a market cap of $2.02 billion, a price-to-earnings ratio of 12.81 and a beta of 0.73.
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting the consensus estimate of $0.19. The company had revenue of $114.49 million during the quarter, compared to analysts’ expectations of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The business’s revenue for the quarter was down .3% on a year-over-year basis. During the same period last year, the firm earned $0.11 EPS. On average, analysts anticipate that ADMA Biologics Inc will post 0.8 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research firms have commented on ADMA. Mizuho reduced their price objective on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday. Raymond James Financial initiated coverage on ADMA Biologics in a research note on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 target price for the company. Wall Street Zen cut ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Finally, Canaccord Genuity Group decreased their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $18.67.
Get Our Latest Analysis on ADMA Biologics
ADMA Biologics Profile
ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.
Featured Articles
- Five stocks we like better than ADMA Biologics
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
